(Q53066623)

English

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

scientific article published on 12 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

26

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

author name string

Philippe A Cassier

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Antoine Italiano

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Carlos A Gomez-Roca

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Christophe Le Tourneau

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Maud Toulmonde

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Michael A Cannarile

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Carola Ries

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Anne Brillouet

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Claudia Müller

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Anna-Maria Jegg

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Ann-Marie Bröske

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Markus Dembowski

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Katharine Bray-French

13

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Christine Freilinger

14

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Georgina Meneses-Lorente

15

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Monika Baehner

16

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Ross Harding

17

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Jayantha Ratnayake

18

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Keelara Abiraj

19

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Nathalie Gass

20

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Karen Noh

21

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Randolph D Christen

22

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Lidia Ukarma

23

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Emmanuelle Bompas

24

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Jean-Pierre Delord

25

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Dominik Rüttinger

27

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

publication date

12 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

16

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

949-956

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pigmented villonodular synovitis: radiologic-pathologic correlation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pigmented villonodular synovitis: current concepts about diagnosis and management.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Short arm of chromosome 1 aberration recurrently found in pigmented villonodular synovitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Indications for imatinib mesylate therapy and clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Periorbital edema secondary to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe periorbital edema secondary to STI571 (Gleevec).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Macrophages as APC and the dendritic cell myth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900132-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00132-1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/26179200

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53066623&oldid=1417683245"